Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026The Egyptian Journal of HaematologyOpen Access

Clinico-hematological characteristic, lipogram, and some metabolic alteration in chronic phase chronic myeloid leukemia in a patient treated with Tyrosine kinase inhibitor

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMona M. SolimanMHMuhamad R. Abdel HameedNHNoha R. Abdel-Rahman Hamzawy

Discussion

Loading...

Member takes

Overview

Prospective study evaluates metabolic markers as predictors of molecular response in chronic myeloid leukemia, suggesting insights for therapy.

Key Points

  • To evaluate clinico-hematological and metabolic markers as predictors of major molecular response in chronic phase CML treated with TKIs.
  • Prospective cross-sectional study involving 60 adults with chronic phase CML.
  • Patients classified by molecular response status after 6 months of treatment.
  • Clinical data and various blood tests were collected at multiple time points.
  • 50 patients achieved major molecular response (MMR), while 10 did not.
  • Neutrophil-to-lymphocyte ratio and TG/HDL ratio were significantly lower in MMR patients (P < 0.05 and P < 0.01, respectively).
  • Age and comorbidity indices were higher in the no-MMR group (P < 0.05).

Cite This Study

Soliman et al. (2026) studied this question.

synapsesocial.com/papers/6a362f92db0793dc1a53702chttps://doi.org/10.4103/ejh.ejh_4_26
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Thyroid status in chronic phase chronic myeloid leukemia patient treated with Tyrosine Kinase Inhibitor2026
  2. 2Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors—Hematological Changes and Correlation with European Leukemia Network Response Criteria2025
  3. 3Molecular Response to TKI and Exploring the Factors of Treatment Compliance in CML Patients from Assam, India2026
  4. 4Low initial hemoglobin and high-risk additional chromosomal abnormalities predict poor long-term survival in chronic phase chronic myeloid leukemia2026
  5. 5The treatment of patients with chronic myeloid leukemia chronic phase combined with myelofibrosis with tyrosine kinase inhibitors: A Chinese population-based study.2024